Dynavisc
Fziomed, Inc. · Decision date Oct 28, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision for Dynavisc, a traditional 510(k) submitted by Fziomed, Inc. of San Luis Obispo, California, under number K262343. The record lists the device classification name as Mesh, Surgical, Absorbable, Orthopaedics, Reinforcement Of Tendon, regulation number 878.3300, and classification product code OWW. The application was received on 07/10/2026 and decided on 10/28/2026; SESE means the device was cleared for marketing, not granted premarket approval.
The record lists the regulation medical specialty as General & Plastic Surgery and the 510(k) review panel as Orthopedic. It states the submission was not reviewed by a third party, is not a combination product, and has no authorized predetermined change control plan. The public record does not describe the specific device components, materials, or any changed item, and no summary statement is present, so the basis for the equivalence determination remains unknown from this source.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Oct 28, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K262343
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Fziomed, Inc.
- Product code
- OWW
- Decision code
- SESE
- Decision date
- Oct 28, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Mesh, Surgical, Absorbable, Orthopaedics, Reinforcement Of Tendon.
- Applicant
- Fziomed, Inc.
- Product code
- OWW
- FDA device class
- 2
FDA decision timeline
K262343 received
Application receipt date recorded by FDA.
K262343 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code OWW
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
BioChargeK263682 | Nanofiber Solutions, LLC | 510(k) clearance | Nov 5, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Fziomed, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- San Luis Obispo, CA
Sources and methodology
- Original FDA record: K262343
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records